Can I Take Omega-3 (EPA/DHA) with Egrifta (Tesamorelin)?

Direct answer

Omega-3 (EPA/DHA), whether from a dietary supplement or a prescription product, can generally be taken alongside tesamorelin (Egrifta SV). No pharmacokinetic interaction has been described, since tesamorelin is a subcutaneously injected peptide cleared by tissue peptidases while omega-3 fatty acids are absorbed through intestinal lymphatics and metabolized by beta-oxidation. The two do not share a metabolic enzyme, transporter, or absorption pathway. The interaction that matters clinically is pharmacodynamic: both lower triglycerides, so using them together is likely to lower triglycerides more than either alone, and a fasting lipid panel some weeks after starting the combination is a reasonable way to see the combined effect and make sure triglycerides have not fallen further than intended.

Who this applies to, and what tesamorelin and omega-3 actually are

Tesamorelin (Egrifta SV) is a stabilized analogue of endogenous growth hormone-releasing hormone (GHRH). It is given as a once-daily subcutaneous injection and is FDA-approved specifically for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy. It works by stimulating the pituitary to release growth hormone (GH), which in turn raises insulin-like growth factor-1 (IGF-1) and shifts fat metabolism away from visceral fat accumulation. Details on approved indication, dosing, and monitoring requirements are in the FDA-approved prescribing information for Egrifta SV.

Omega-3 fatty acids refers to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), long-chain polyunsaturated fats found in fish oil, algae oil, and krill oil supplements. Two prescription formulations are FDA-approved specifically as triglyceride-lowering drugs: icosapentaenoic acid ethyl ester (brand name Vascepa) and omega-3-acid ethyl esters (brand name Lovaza). Most people asking this question, though, are taking an over-the-counter fish oil supplement rather than a prescription product, and the evidence base and dosing differ meaningfully between the two.

This page is about combining omega-3 with tesamorelin specifically. It does not address omega-3 interactions with antiretroviral therapy, statins beyond a general note, or other supplements.

Is there a pharmacokinetic interaction?

No pharmacokinetic interaction is described in the tesamorelin prescribing information or in general pharmacology of either agent. Tesamorelin is a peptide degraded by tissue peptidases and does not go through hepatic cytochrome P450 metabolism, so it has no known enzyme-based interaction pathway. Omega-3 fatty acids are absorbed through the intestinal lymphatic system and oxidized as fuel; they are not metabolized through CYP450 pathways in a way that would compete with tesamorelin. Because tesamorelin is injected and never enters the gastrointestinal tract, taking omega-3 capsules with food, at a different time of day, or at any particular interval from the injection has no bearing on tesamorelin's absorption or effect. This is an established point, not a plausible-but-unproven one: it follows directly from the two drugs' distinct routes of administration and clearance mechanisms rather than from a dedicated interaction study.

The pharmacodynamic overlap: triglycerides

Both agents lower triglycerides, but through separate biological routes. Tesamorelin's effect on lipids is downstream of visceral fat reduction: as GH rises, visceral fat mobilizes, and the liver's substrate for making triglyceride-rich VLDL particles decreases over weeks to months. Omega-3 fatty acids act more directly on the liver, suppressing VLDL-triglyceride assembly and increasing its clearance, an effect that shows up faster, typically within weeks.

Because the two triglyceride-lowering mechanisms are different, adding omega-3 to a tesamorelin regimen is pharmacologically plausible as an additive rather than a redundant intervention. This is a plausible extrapolation from how each drug works individually rather than a claim tested in a dedicated trial of the combination, and it should be verified in the primary literature before being repeated as an established fact. The practical implication is straightforward regardless of the exact magnitude: patients with substantially elevated triglycerides at baseline are the most likely to benefit from combining the two, while patients whose triglycerides are only mildly elevated should have a follow-up lipid panel to confirm levels have not dropped further than clinically desired.

Antiplatelet effect: what to ask about

High-dose omega-3 (commonly cited as roughly above 3 grams of combined EPA+DHA per day, doses more typical of prescription formulations than standard over-the-counter fish oil) can mildly inhibit platelet aggregation, partly through reduced thromboxane A2 production. This is a recognized pharmacologic effect of omega-3 fatty acids at higher doses and is the reason prescription omega-3 labeling includes caution around concurrent anticoagulant or antiplatelet use.

Tesamorelin has no antiplatelet mechanism of its own, so it does not add to this risk directly. The relevant question is not tesamorelin and omega-3 together, but omega-3 dose together with any blood thinner or antiplatelet drug the patient is already taking (aspirin, clopidogrel, warfarin, or a direct oral anticoagulant). For a patient on tesamorelin who is not on any of these medications, standard-dose omega-3 supplementation does not raise a distinct bleeding concern. For a patient on both a blood thinner and high-dose omega-3, that conversation belongs with the prescribing clinician regardless of the tesamorelin, and a specific bleeding-risk number cannot be stated here without verification against the primary literature for the individual's exact regimen.

Evidence boundary: what is established, what is plausible, what is not established

Established: Tesamorelin and omega-3 fatty acids use different metabolic and clearance pathways, so no pharmacokinetic interaction is expected. Both classes independently lower triglycerides through separate mechanisms. High-dose omega-3 has a recognized mild antiplatelet effect that is the basis for caution with concurrent anticoagulants, independent of tesamorelin.

Plausible but not established by a dedicated study: That combining tesamorelin with omega-3 produces a larger triglyceride reduction than either alone in HIV-associated lipodystrophy specifically. This follows from the two agents' separate mechanisms but has not been confirmed here by a trial that tested the combination directly, and any specific percentage reduction attributed to the pairing should be treated as unverified until checked against the primary literature.

Not established: Any cardiovascular outcome benefit from combining these two specific agents. Trials of prescription omega-3 formulations have shown different cardiovascular outcomes depending on the specific formulation and comparator, and none of those trials enrolled a population selected for concurrent tesamorelin use. Extrapolating a cardiovascular benefit from tesamorelin plus omega-3 in HIV-associated lipodystrophy is not supported by direct evidence.

Evidence-status interaction assessment

Use this table to see what level of confidence applies to each claim discussed above, and what still needs a clinician or pharmacist to verify against the current label and primary literature before acting on it.

Monitoring that makes sense for this combination

• A fasting lipid panel before starting either agent, if not already available, gives a true baseline. Nonfasting triglycerides run noticeably higher and can make triglyceride change harder to interpret.
• A follow-up fasting lipid panel some weeks after adding omega-3 to an existing tesamorelin regimen (or vice versa) helps confirm the direction and rough size of the combined effect, and catches triglycerides that have fallen further than intended.
• IGF-1 monitoring should continue on whatever schedule the prescriber has set for tesamorelin, per the Egrifta SV label; omega-3 is not expected to change IGF-1 levels, but IGF-1 monitoring is part of tesamorelin's own safety monitoring independent of any supplement use.
• Anyone on a blood thinner or antiplatelet medication who wants to start omega-3 at a higher, prescription-range dose should raise it with the prescribing clinician or a pharmacist before starting, rather than relying on a general internet reference for a bleeding-risk number specific to their situation.
• Tesamorelin carries a labeled concern about worsening glucose tolerance because growth hormone is insulin-antagonistic; this is unrelated to omega-3 and should be monitored as directed regardless of supplement use.

What guidelines say

HIV treatment guidelines address lipid management mainly through statin therapy and antiretroviral regimen selection rather than through a dedicated recommendation on omega-3 supplementation alongside GH-axis therapies like tesamorelin. Readers who want the current guideline language on lipid management in HIV should check the HIV.gov clinical guidelines directly, since guideline text changes over time and a summarized version can go stale. No major guideline body reviewed for this article flags omega-3 as contraindicated with tesamorelin or other GHRH analogues, but the absence of a flag is not the same as a guideline explicitly endorsing the combination.

Practical points for patients

• Continue tesamorelin injections on the prescribed schedule; adding an oral omega-3 supplement does not require any change to injection timing, site, or reconstitution.
• If choosing an over-the-counter fish oil, check the supplement facts panel for the actual combined EPA+DHA content per serving rather than the total "fish oil" milligram amount, since the two numbers are often very different.
• If triglycerides remain significantly elevated despite tesamorelin and standard-dose omega-3, ask about a prescription omega-3 option (Vascepa or Lovaza), which has a specific FDA-approved indication for severe hypertriglyceridemia and a more concentrated, standardized dose.
• Always disclose all supplements, including fish oil, to the prescribing team, since undisclosed supplement use can make it harder to interpret lipid changes correctly.
• Report any unusual or easy bruising to the clinical team, particularly at higher omega-3 doses or when also taking a blood thinner.

When to seek urgent care

Seek urgent medical attention for signs of unusual bleeding (blood in stool or urine, unexplained large bruises, prolonged bleeding from a cut), for signs of a severe allergic reaction, or for symptoms of markedly elevated blood sugar (excessive thirst, frequent urination, confusion) while on tesamorelin. These are general safety points related to the individual drug classes rather than specific evidence of a combination risk.